180 related articles for article (PubMed ID: 24260468)
1. Prognostic value of PLAGL1-specific CpG site methylation in soft-tissue sarcomas.
Peille AL; Brouste V; Kauffmann A; Lagarde P; Le Morvan V; Coindre JM; Chibon F; Bresson-Bepoldin L
PLoS One; 2013; 8(11):e80741. PubMed ID: 24260468
[TBL] [Abstract][Full Text] [Related]
2. Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma.
Seidel C; Bartel F; Rastetter M; Bluemke K; Wurl P; Taubert H; Dammann R
Int J Cancer; 2005 Apr; 114(3):442-7. PubMed ID: 15551306
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling identifies the role of Zac1 in cervical cancer metastasis.
Su HC; Wu SC; Yen LC; Chiao LK; Wang JK; Chiu YL; Ho CL; Huang SM
Sci Rep; 2020 Jul; 10(1):11837. PubMed ID: 32678267
[TBL] [Abstract][Full Text] [Related]
4. Loss of expression of ZAC/PLAGL1 in diffuse large B-cell lymphoma is independent of promoter hypermethylation.
Valleley EM; Cordery SF; Carr IM; MacLennan KA; Bonthron DT
Genes Chromosomes Cancer; 2010 May; 49(5):480-6. PubMed ID: 20175198
[TBL] [Abstract][Full Text] [Related]
5. Both gene deletion and promoter hyper-methylation contribute to the down-regulation of ZAC/PLAGL1 gene in gastric adenocarcinomas: a case control study.
Li Z; Ding Y; Zhu Y; Yin M; Le X; Wang L; Yang Y; Zhang Q
Clin Res Hepatol Gastroenterol; 2014 Dec; 38(6):744-50. PubMed ID: 25091631
[TBL] [Abstract][Full Text] [Related]
6. PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis.
Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Maslowski Z; Kmiec Z
Anticancer Res; 2016 Feb; 36(2):617-24. PubMed ID: 26851016
[TBL] [Abstract][Full Text] [Related]
7. Alteration in the expression of MGMT and RUNX3 due to non-CpG promoter methylation and their correlation with different risk factors in esophageal cancer patients.
Saikia S; Rehman AU; Barooah P; Sarmah P; Bhattacharyya M; Deka M; Deka M; Goswami B; Husain SA; Medhi S
Tumour Biol; 2017 May; 39(5):1010428317701630. PubMed ID: 28468586
[TBL] [Abstract][Full Text] [Related]
8. Tissue-specific imprinting of the ZAC/PLAGL1 tumour suppressor gene results from variable utilization of monoallelic and biallelic promoters.
Valleley EM; Cordery SF; Bonthron DT
Hum Mol Genet; 2007 Apr; 16(8):972-81. PubMed ID: 17341487
[TBL] [Abstract][Full Text] [Related]
9. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma.
Seidel C; Schagdarsurengin U; Blümke K; Würl P; Pfeifer GP; Hauptmann S; Taubert H; Dammann R
Mol Carcinog; 2007 Oct; 46(10):865-71. PubMed ID: 17538946
[TBL] [Abstract][Full Text] [Related]
10. Association of low p16INK4a and p15INK4b mRNAs expression with their CpG islands methylation with human hepatocellular carcinogenesis.
Qin Y; Liu JY; Li B; Sun ZL; Sun ZF
World J Gastroenterol; 2004 May; 10(9):1276-80. PubMed ID: 15112341
[TBL] [Abstract][Full Text] [Related]
11. LMX1B mRNA expression and its gene body CpG methylation are valuable prognostic biomarkers for laryngeal squamous cell carcinoma.
Fan L; Zhang A; Deng P
Biomed Pharmacother; 2019 Sep; 117():109174. PubMed ID: 31387183
[TBL] [Abstract][Full Text] [Related]
12. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
13. HOXD13 methylation status is a prognostic indicator in breast cancer.
Zhong Z; Shan M; Wang J; Liu T; Xia B; Niu M; Ren Y; Pang D
Int J Clin Exp Pathol; 2015; 8(9):10716-24. PubMed ID: 26617782
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.
Akhoondi S; Lindström L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grandér D; Sangfelt O
Breast Cancer Res; 2010; 12(6):R105. PubMed ID: 21122106
[TBL] [Abstract][Full Text] [Related]
15. CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer.
Stefansson OA; Hermanowicz S; van der Horst J; Hilmarsdottir H; Staszczak Z; Jonasson JG; Tryggvadottir L; Gudjonsson T; Sigurdsson S
BMC Cancer; 2017 Jul; 17(1):469. PubMed ID: 28679371
[TBL] [Abstract][Full Text] [Related]
16. Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
Chai RC; Zhang KN; Liu YQ; Wu F; Zhao Z; Wang KY; Jiang T; Wang YZ
CNS Neurosci Ther; 2019 Mar; 25(3):314-322. PubMed ID: 30117294
[TBL] [Abstract][Full Text] [Related]
17. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
19. LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer.
Abdollahi A; Pisarcik D; Roberts D; Weinstein J; Cairns P; Hamilton TC
J Biol Chem; 2003 Feb; 278(8):6041-9. PubMed ID: 12473647
[TBL] [Abstract][Full Text] [Related]
20. A tissue-specific promoter derived from a SINE retrotransposon drives biallelic expression of PLAGL1 in human lymphocytes.
Smith CEL; Alexandraki A; Cordery SF; Parmar R; Bonthron DT; Valleley EMA
PLoS One; 2017; 12(9):e0185678. PubMed ID: 28957425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
